: Jaguar Health’s stock drops after results supporting ‘paramount’ trial have not been received yet
Shares of Jaguar Health Inc. JAGX were mauled for a 21.2% loss in morning trading Tuesday, after the drug maker said it has not yet received data supporting the Phase 3 trial of its treatment of diarrhea in cancer patients receiving therapy. The compan...
21
Nov
2023